SecBot SecBot
6-K ·Filed Sep 1, 2026

GSK

GSK plc
BULLISH
Impact 6/10
Horizonmonths Processed2mo ago SEC0001654954-26-007998
Notable filing: 6-K
Actionable Insight ▲ Bullish

GSK's mRNA flu vaccine candidate advancing to Phase III is a positive pipeline catalyst, but revenue impact is years away. Monitor Phase III enrollment and interim data readouts. The Fast Track designation may accelerate regulatory review. Competitors include Moderna and Pfizer/BioNTech in the mRNA flu space.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$50.66
T+0 close · Sep 1, 2026 · via day close
Latest settled
−3.93%
T+20 · $48.67 · next T+60 in 8d
Vs SPY
−5.11%
α at T+20
Latest observation
+1.31%
T+52 · FF3 residual α
  1. T+0 · Sep 1 $50.66entry
  2. T+1 · 3mo ago −0.43%α −0.88% · $50.44
  3. T+5 · 2mo ago −4.01%α −4.09% · $48.63
  4. T+20 · 7w ago −3.93%α −5.11% · $48.67
  5. T+53 · todayOpen
  6. T+60 · in 8d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK announced positive Phase II data for its mRNA seasonal flu vaccine candidate (FLUm3HA.b-3NA), showing higher immune responses vs. standard and high-dose vaccines in younger and older adults. The candidate targets both HA and NA antigens, a novel approach for mRNA flu vaccines. GSK will initiate a Phase III efficacy trial in September 2026, and the FDA granted Fast Track designation in July 2026. This is a positive pipeline catalyst but remains early-stage with no near-term revenue impact.

Key Facts

  • Phase II data showed higher immune responses vs. standard and high-dose flu vaccines in younger and older adults.
  • GSK intends to start a Phase III efficacy trial in September 2026.
  • FDA granted Fast Track designation in July 2026.
  • Vaccine candidate targets both haemagglutinin (HA) and neuraminidase (NA) antigens.
  • This will be the first Phase III trial of an mRNA flu vaccine designed to target both HA and NA.
  • The vaccine candidate is not approved anywhere in the world.

Financial Impact

No financial figures disclosed. Pipeline milestone with potential future revenue if approved; Phase III trial costs are R&D expense.

researchAndDevelopmentExpenses

Risk Factors

  • Phase III trial may fail to meet efficacy or safety endpoints.
  • mRNA flu vaccine market is competitive with Moderna and Pfizer/BioNTech advancing similar candidates.
  • Regulatory approval and commercial launch are several years away.
  • Vaccine not yet approved anywhere; no guarantee of eventual approval.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (32 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-007998
Document: 0001654954-26-007998-index-headers.html0001654954-26-007998
Document: 0001654954-26-007998-index.html0001654954-26-007998
Document: 0001654954-26-007998.txt0001654954-26-007998

US Market Status

Market Closed · Opens Wed (10h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 1, 2026